|
Single center experience with alpelisib-fulvestrant in heavily pretreated women with HR(+), HER-2 (−) metastatic breast cancer. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; AstraZeneca; MSD; Roche |
Consulting or Advisory Role - MSD |
Research Funding - Abbvie; Amgen; Bristol Myers Squibb Foundation; Lilly; Mirati Therapeutics; Novartis |
|
|
Honoraria - AstraZeneca; Bristol Myers Squibb Foundation; Merck; Novartis |
Consulting or Advisory Role - AstraZeneca; Bristol Myers Squibb Foundation; Merck |
Travel, Accommodations, Expenses - Accord Healthcare; MSD; Saint Louis University School of Medicine (SLUSOM) |
|
|
Honoraria - Bristol Myers Squibb Foundation; MSD; Novartis |
Consulting or Advisory Role - Merck Serono |
|
|
Consulting or Advisory Role - Leo Pharma; Pfizer |
|
|
Honoraria - Amgen; AstraZeneca/Merck; Novartis; Pfizer; Roche |
Consulting or Advisory Role - AstraZeneca/Merck; Ipsen; Pfizer |
Research Funding - Amgen (Inst); AstraZeneca/Merck (Inst); Lilly (Inst); Novartis (Inst); Roche |
Travel, Accommodations, Expenses - Pfizer |